Code No.
(Generic Name) |
Efficacy Classification |
Target Disease |
Phase |
Notes |
| KD2-305 |
Blood plasma product |
Suppression of bleeding tendency in patients with blood coagulation factor Ⅷ or factor Ⅸ deficiency who have coagulation factor inhibitors |
Approved |
Discovered in-house |
| KD-370 |
Vaccine |
Pentavalent vaccine against diphtheria, tetanus, pertussis, poliovirus, and haemophilus influenza type b |
Filed (Under review) |
|
ME3208
(Belumosudil) |
ROCK2 inhibitor |
Chronic Graft Versus Host Disease |
Filed (Under review, South Korea) |
Development: Romeck Pharma, LLC |
| ARCT-154 |
Vaccine |
Next generation mRNA vaccine against COVID-19 |
Filed (Under review)
Phase Ⅲ |
Partnership: CSL Seqirus (Australia) |
| DMB-3115 |
Biosimilar |
Plaque psoriasis/Psoriatic arthritis/Crohn's disease/Ulcerative colitis |
In preparation for application (Overseas) |
Co-development: Dong-A ST Co., Ltd. (South Korea)
Out-license: Intas Pharmaceuticals Ltd. (India) |
| KD-414 |
Vaccine |
Inactivated vaccine against COVID-19 (Adults) |
Phase Ⅲ (Adults under 40)*
Phase Ⅱ / Ⅲ
Phase Ⅰ / Ⅱ |
* Multi-Regional Clinical Trials |
| KD-414 |
Vaccine |
Inactivated vaccine against COVID-19 (Pediatric) |
Phase Ⅲ
Phase Ⅱ / Ⅲ |
|
| ME3208 (Belumosudil) |
ROCK2 inhibitor |
Chronic Graft Versus Host Disease |
Phase Ⅲ |
Development: Romeck Pharma, LLC |
| HBI-8000 (Tucidinostat) |
HDAC inhibitor |
Unresectable or metastatic melanoma |
Phase Ⅲ (Multinational study including Japan) |
Co-development: HUYABIO International, LLC (USA)
Multi-Regional Clinical Trial |
| OP0595 (Nacubactam) |
β-lactamase inhibitor |
Infections caused by carbapenem-resistant bacteria |
Phase Ⅲ (Multinational study including Japan) |
Discovered in-house
Multi-Regional Clinical Trials |
| ME3183 |
Selective PDE4 inhibitor |
Psoriasis |
Phase Ⅱ (Overseas) |
Discovered in-house |
| HBI-8000 (Tucidinostat) |
HDAC inhibitor |
Relapsed or refractory B-cell non-Hodgkin's lymphoma |
Phase Ⅰb / Ⅱ |
In-license: HUYABIO International, LLC (USA) |
| DMB-3115 |
Biosimilar |
Plaque psoriasis/Psoriatic arthritis/Crohn's disease/Ulcerative colitis |
Phase Ⅰ |
Co-development: Dong-A Socio Holdings Co., Ltd.
(South Korea) |
| KD-382 |
Vaccine |
Quadrivalent vaccine against dengue fever |
Phase Ⅰ (Overseas) |
|
| KD2-396 |
Vaccine |
Hexavalent vaccine against diphtheria, tetanus, pertussis, poliovirus, haemophilus influenza type b, and Hepatitis B virus |
Phase Ⅰ |
|
